[EN] Lung cancer is a malignant disease with high mortality and poor prognosis, frequently diagnosed at advanced stages. Nowadays, immense progress in treatment has been achieved. However, the present scenario continues ...
[EN] Background: Epidermal growth factor receptor (EGFR) is overexpressed in a variety of epithelial malignancies including lung cancer. A soluble fragment of the EGFR extracellular domain (sEGFR) can be detected in the ...
[EN] Background: Platinum doublets are standard chemotherapy for advanced non-small-cell lung cancer (NSCLC). The aim of this study was to assess whether neutropenia is: (1) an indicator for treatment efficacy, or (2) ...
Sirera Pérez, Rafael; Bremnes, Roy M.; Cabrera, Andrea; Jantus Lewintre, Eloisa; Sanmartin, Elena; Blasco, Ana; del Pozo, Nieves; Rosell, Rafael; Guijarro, Ricardo; Galbis, Jose; Sanchez, Jose Javier; Camps, Carlos(Lippincott, Williams & Wilkins, 2011-02)
Background: Circulating DNA is observed at higher concentrations in patients with lung cancer than in controls. Qualitative and quantitative analysis of circulating DNA is a promising noninvasive tool. Our aim was to ...
Guerrero Mata, Juan Francisco(Universitat Politècnica de València, 2024-10-14)
[ES] El cáncer es una de las principales causas de muerte en el mundo y se espera que su impacto aumente en los próximos años, siendo el cáncer de pulmón aquel que presenta mayor incidencia y mortalidad. El adenocarcinoma, ...
Duréndez Sáez, María Elena(Universitat Politècnica de València, 2024-03-31)
[ES] A pesar de los nuevos avances en el tratamiento del cáncer de pulmón, su tasa de incidencia y mortalidad siguen en cabeza en todo mundo. Concretamente, el cáncer de pulmón no microcítico (CPNM) representa casi el 85% ...
[EN] Background: In advanced-stage (IIIB or IV) non-small-cell lung cancer (NSCLC), combination chemotherapy has demonstrated response rates of 20% and a 1-year survival rate of 30%. We conducted a multicentre, open-label, ...